Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide for adult COVID-19 pneumonia with hypoxic respiratory failure
ISRCTN16806663Phase 2Completed
- Sponsor
- Amrita Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nitric oxide and sildenafil in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Amrita Hospital. Primary endpoint: Viral load. Started Sep 2020; status: completed.
02
Drugs
nitric oxidesildenafil
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ISRCTN16806663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16806663.